Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure

Uribe‐Herranz, Mireia; Klein-González, Nela; Rodríguez‐Lobato, Luis Gerardo; Juan, Manel; Larrea, Carlos Fernández de

doi:10.3390/ijms22031026

Cited by 37 publications

(18 citation statements)

References 194 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The studies that addressed GM modifications during chemotherapy for childhood AL have identified antibiotics, immunosuppression, dietary changes and direct toxicity among the contributing factors to intestinal ecosystem alterations [20][21][22] (table 1). GM diversity decreases significantly after intensive induction and reinduction protocols, with a slight rebound in the time period after recovery from induction 23 .…”

Section: Gut Microbiome Modifications During Chemotherapymentioning

confidence: 99%

Gut microbiome in pediatric acute leukemia: from predisposition to cure

et al. 2021

View full text Add to dashboard Cite

The gut microbiome (GM) has emerged as a key factor in the genesis and progression of many diseases. The intestinal bacterial composition is also able to influence treatment-related side effects and even efficacy of oncological therapies. Acute leukemia (AL) is the most common cancer among children and the most frequent cause of death from cancer during childhood. Outcome has improved considerably over the past four decades, with the current long-term survival for acute lymphoblastic leukemia being approximately 90%. However, several acute toxicities and long-term sequela are associated with the multimodal therapy-protocols applied in these patients. Specific GM configurations could contribute in the multistep developmental hypothesis for leukemogenesis. Moreover, GM alterations occur during the AL therapeutic course and are associated with treatment-related complications, especially during hematopoietic stem cell transplantation. The GM perturbation could last even after the removal of microbiome-modifying factors, like antibiotics, chemotherapeutic drugs or allo-immune reactions, contributing to several health-related issues in AL survivors. The aim of this paper is to provide a comprehensive review of the chronological changes of GM in children with AL, from predisposition to cure. The underpinning biological processes and the potential interventions to modulate the GM towards a potentially health-promoting configuration are also highlighted.

show abstract

Section: Gut Microbiome Modifications During Chemotherapymentioning

confidence: 99%

Gut microbiome in pediatric acute leukemia: from predisposition to cure

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a large number of clinical trials CAR T cell targeting tumor-associated antigens have been found cause damage to normal tissue with low expression of tumor-associated antigens during the process of recognizing and killing tumor cells, which is referred to as the off-target effect ( 25 ). Moreover, the reasons behind the success of CAR T cells in the treatment of hematologic tumors is that they can migrate in blood, lymph nodes, and bone marrow to interact with cancer cells ( 26 ). By dynamic imaging microscopy on fresh tumor slices from nine patients, Donnadieu et al.…”

Section: Current Roadblocks In Car-t Cell For Solid Tumorsmentioning

confidence: 99%

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Min

2022

Front. Immunol.

View full text Add to dashboard Cite

Chimeric antigen receptor T cell (CAR-T) therapy for the treatment of hematologic tumors has achieved remarkable success, with five CAR-T therapies approved by the United States Food and Drug Administration. However, the efficacy of CAR-T therapy against solid tumors is not satisfactory. There are three existing hurdles in CAR-T cells for solid tumors. First, the lack of a universal CAR to recognize antigens at the site of solid tumors and the compact tumor structure make it difficult for CAR-T cells to locate in solid tumors. Second, soluble inhibitors and suppressive immune cells in the tumor microenvironment can inhibit or even inactivate T cells. Third, low survival and proliferation rates of CAR-T cells in vivo significantly influence the therapeutic effect. As an emerging method, nanotechnology has a great potential to enhance cell proliferation, activate T cells, and restarting the immune response. In this review, we discuss how nanotechnology can modify CAR-T cells through variable methods to improve the therapeutic effect of solid tumors.

show abstract

“…Several studies indicate the implication of altered microbiome (dysbiosis) in different metabolic disorders (diabetes, obesity) [36][37][38] , inflammatory bowel disease 39-41 autism [42][43][44] , and neurodegenerative diseases Parkinson's disease [45][46][47][48] , Alzheimer disease 49,50 multiple sclerosis [51][52][53] . Recent scientific advances have significantly contributed to our understanding of the complex connection between the microbiome and cancer, solid tumors, and hematological malignancies alike [54][55][56][57] . As it appears in the literature, microorganisms and microbial elements such as lipopolysaccharides (LPS) can up-regulate Toll-like Receptors (TLR)s, which can provoke activation of nuclear factor-kB (NF-kB), which is critical for controlling tumor-associated inflammation 58,59 , invasion, growth, survival, and immunosuppression 60 .…”

Section: Antibiotic Classesmentioning

confidence: 99%

Possible Role of the Antibiotic-Modified Microbiome in the Development of Hematological Malignancies in European Countries

Ternák¹,

Berényi²,

Németh³

et al. 2022

Preprint

View full text Add to dashboard Cite

Hematological malignancies are considered the fifth most common cancer in the world. Several risk factors and probable etiological agents have been suspected in the pathomechanism of those malignancies as infections, chemicals, irradiation, etc., and recently, the contribution of the altered gut flora, dysbiosis, was identified also as a possible additional factor to the existing ones. Host, and external factors, like antibiotics, which were identified as a major disruptor of the "normal" gut flora, influence the composition of the microbiome. Considering the several-fold differences in antibiotic consumption patterns and the incidence of hematological malignancies in European countries, the hypothesis was raised that the dominant consumption of certain antibiotic classes might influence the incidence of different hematological malignancies through the modification of gut flora. Comparisons were performed between the average antibiotic consumption databases reported yearly by ECDC (2009-2019) and the incidence rate of Hodkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and leukemia (LEU) estimated for 2020 in 30 European countries. Applying Spearman calculations, significant positive correlation has been found between the incidence of HL and tetracycline (J01A) consumption (r = 0.399, p = 0,029), NHL and narrow spectrum, beta-lactamase resistant penicillin (J01CF) (r = 0.580, p = 0,001), MM and tetracycline (r = 0.492, p = 0.006), penicillin (J01C) (r = 0.366, p = 0.047), narrow spectrum, beta-lactamase resistant penicillin (J01CF) (r = 0.574, p = 0.001), while strong, significant negative correlation has been recorded between NHL and cephalosporin (r = -0,460, p = 0,011), and quinolone (r = -0,380, p = 0,038). The incidence of LEU did not show any positive or negative association with any antibiotic classes. It is concluded that certain antibiotic classes, in addition to other putative factors, might promote or inhibit the development of different hematological malignancies.

show abstract

Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure

Cited by 37 publications

References 194 publications

Gut microbiome in pediatric acute leukemia: from predisposition to cure

Gut microbiome in pediatric acute leukemia: from predisposition to cure

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Possible Role of the Antibiotic-Modified Microbiome in the Development of Hematological Malignancies in European Countries

Contact Info

Product

Resources

About